NCT03758469View on ClinicalTrials.gov

A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Rifampin Capsules

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 14, 2018

Primary Completion Date

January 31, 2019

Study Completion Date

March 10, 2019

Conditions
AnesthesiaSedation
Interventions
DRUG

HSK3486

Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.

DRUG

rifampin , HSK3486

Sequence 2: Orally take 600 mg rifampin once a day for 8 consecutive days in the morning on an empty stomach, followed by 1 min intravenous infusion of 0.4 mg/kg HSK3486 30 min later.

Trial Locations (1)

Unknown

Shanghai Public Health Clinical Center, Shanghai

All Listed Sponsors
lead

Sichuan Haisco Pharmaceutical Group Co., Ltd

INDUSTRY

NCT03758469 - A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Rifampin Capsules | Biotech Hunter | Biotech Hunter